Soluble tissue factor and tissue factor pathway inhibitor in cardiovascular disease

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 3, 2007, Pages 472-474

  Toschi, Vincenzo ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CORONARY ARTERY; CORONARY ARTERY THROMBOSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; HEART MUSCLE INJURY; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; THROMBOGENICITY; ANGINA PECTORIS; BLOOD; BLOOD CLOTTING; CORONARY ARTERY ATHEROSCLEROSIS; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; METABOLISM; MORTALITY; PREDICTION AND FORECASTING; PROGNOSIS;

ANGINA PECTORIS; BIOLOGICAL MARKERS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; HUMANS; LIPOPROTEINS; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; THROMBOPLASTIN;

EID: 34247555475     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02402.x     Document Type: Note

References (25)

1. Mackman N. Role of tissue factor in hemostasis thrombosis and vascular development. Athroscler Thromb Vasc Biol 2004; 24: 1015-22.
2. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue Factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
3. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high risk plaque. J Am Coll Cardiol 2005; 46: 937-54.
4. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human athrosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-87.
5. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47: C13-8.
6. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352: 1686-95.
7. Deguchi J-O, Aikawa M, Tung C-H, Aikawa E, Kim D-E, Ntziachristos V, Weissleder R, Libby P. Inflammation in atherosclerosis. Visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006; 114: 55-62.
8. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27: 15-26.
9. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
10. Merlini PA, Ardissino D, Bauer KA, Oltrona L, Pezzano A, Bottasso B, Sosemberg RD, Mannucci PM. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 1997; 17: 1325-30.
11. Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Munzel T, Peetz D, Nicaud V, Juhan-Vague I, Tiret L, for the Athero Gene Investigators. The prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: The Athero Gene Study. J Thromb Haemost 2007; 5: 475-82.
12. Giesen PL, Rauch U, Bohrman B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-born tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
13. Camera M, Frigerio M, Toschi V, Brambilla M, Rossi F, Cottell DC, Maderna P, Parolari A, Bonzi R, De Vincenti O, Tremoli E. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol 2003; 23: 1690-6.
14. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930-2.
15. Tosojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Clin Pathol 2001; 158: 1039-51.
16. Cirillo P, Golino P, CalabròP, CalìG, Ragni M, De Rosa S, Cimmino G, Pacileo M, De Palma R, Forte L, Gargiulo A, Corigliano FG, Angri V, Spagnolo R, Nitch L, Chiariello M. C-reactive protein induces tissue factor expression and promotes smooth muscle and andothelial dell proliferation. Cardiovascular Res 2005; 68: 47-55.
17. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
18. Keuren JF, Magdeleyns EJ, Govers-Riemslag JW, Lindhout T, Curves J. Effect of storage-induced platelet microparticles on the initiation and propagation phase of blood coagulation. Br J Haematol 2006; 134: 307-13.
19. Szotowski B, Antoniak S, Poller W, Schultheiss H-P, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96: 1233-9.
20. Schecter AD, Spirn B, Rossikhina M, Giesen PLA, Bogdanov V, Fallon JT, Fisher EA, Schnapp LM, Nemerson Y, Taubman MB. Release of active tissue factor by human arterial smooth muscle cells. Circ Res 2000; 87: 126-32.
21. Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A. Multiple atherosclerotic plaque rupture in acute coronary syndrome. A three-vessel intravascular ultrasound study. Circulation 2006; 106: 804-8.
22. Othani T, Mizote I, Oyabu J, Okada K, Hirayama A, Kodama K. Number of yellow plaques detected in a coronary artery is associated with future risk of acute coronary syndrome. J Am Coll Cardiol 2006; 47: 2194-200.
23. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I; PRIME Study Group: Endothelial cell markers and risk of coronary heart disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004; 109: 1343-8.
24. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao T, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-13.
25. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.